ArticleClinical research in cardiology : official journal of the German Cardiac Society2011
Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 19 citations in OpenAlex.
- Serum Myeloperoxidase Activity Is Associated with Hoehn-Yahr Staging and Striatal Dopamine-Transporter Binding in Parkinson's Disease.Movement disorders clinical practice · 2025Article
- Association between serum myeloperoxidase enzyme activity and Parkinson's disease status.NPJ Parkinson's disease · 2025Article
- Nitrotyrosine, Nitrated Lipoproteins, and Cardiovascular Dysfunction in Patients with Type 2 Diabetes: What Do We Know and What Remains to Be Explained?Antioxidants (Basel, Switzerland) · 2022Review
- Effects of atorvastatin on atrial remodeling in a rabbit model of atrial fibrillation produced by rapid atrial pacing.BMC cardiovascular disorders · 2016Article
- A combined clinical and biomarker approach to predict diuretic response in acute heart failure.Clinical research in cardiology : official journal of the German Cardiac Society · 2016Article
- Plasma Nitration of High-Density and Low-Density Lipoproteins in Chronic Kidney Disease Patients Receiving Kidney Transplants.Mediators of inflammation · 2015Article
- Fenofibrate improves endothelial function and plasma myeloperoxidase in patients with type 2 diabetes mellitus: an open-label interventional study.Diabetology & metabolic syndrome · 2014Article
- Association of coronary atherosclerotic burden with clinical presentation and prognosis in patients with stable and unstable coronary artery disease.Clinical research in cardiology : official journal of the German Cardiac Society · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe present study investigated whether therapy with statins, beta-blockers and angiotensin-converting enzyme (ACE) inhibitors on admission affects the plasma level of myeloperoxidase (MPO) in patients with coronary artery disease (CAD).
methodsThis study included a consecutive series of 680 patients with angiographically confirmed CAD: 382 patients with stable CAD, 107 patients with unstable angina and 191 patients with ST-segment elevation acute myocardial infarction. Blood samples for MPO measurement were taken before angiography prior to heparin administration.
resultsOn admission, 316 patients were receiving statins, 432 patients were receiving beta-blockers and 354 patients were receiving ACE inhibitors. MPO level was: 65.5 [48.8-101.6] μg/L among patients on statin therapy versus 86.7 [56.0-159.9] μg/L among patients without statin therapy (P < 0.001); 68.1 [50.1-105.1] μg/L among patients on beta-blocker therapy versus 97.3 [56.0-181.9] μg/L among patients without beta-blocker therapy (P < 0.001) and 65.5 [49.2-102.0] μg/L among patients receiving ACE inhibitors versus 92.0 [56.1-171.1] μg/L among patients not receiving ACE inhibitors on admission (P < 0.001). The MPO-lowering effect of these drugs was observed only in patients with acute coronary syndrome but not in patients with stable CAD. The multivariable analysis, adjusting for cardiovascular risk factors, clinical variables and concomitant therapy identified beta-blockers on admission as an independent correlate of lower MPO levels (P = 0.016).
conclusionsIn patients with symptomatic CAD, beta-blocker therapy on admission was independently associated with lower levels of plasma MPO. Pre-admission therapy with statins, beta-blockers or ACE inhibitors reduced MPO levels in patients with acute coronary syndromes, but not in patients with stable CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.